Abstract
What is known and objective: Immune destruction and decreased platelet production are major components of immune thrombocytopenia (ITP) pathogenesis. The aim of this study was to critically evaluate the role of combination therapy in relapsed/refractory ITP and the concept of medication tapering/discontinuation. Comment: Although a number of combination regimens have been reported, little is published on combining immunosuppression with thrombopoietin receptor agonists (TPO-RAs). We report a case of refractory ITP successfully treated with combination immunosuppression added to eltrombopag. An aggressive combination approach resulted in complete remission and allowed for stepwise drug tapering. What is new and conclusion: Combination immunosuppression can potentiate the effect of TPO-RAs. This mechanistically reasonable strategy could result in a more rapid response than the more popular, sequential, single-agent strategy. Stepwise tapering can be successfully implemented. Comparing sequential single-agent therapy with early combination approach warrants a more extensive study.
| Original language | English |
|---|---|
| Pages (from-to) | 453-458 |
| Number of pages | 6 |
| Journal | Journal of Clinical Pharmacy and Therapeutics |
| Volume | 41 |
| Issue number | 5 |
| DOIs |
|
| State | Published - Oct 1 2016 |
Keywords
- eltrombopag
- immune thrombocytopenia
- immunosuppression
- refractory
- thrombopoietin